Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Scinai Immunotherapeutics (SCNI)
NASDAQ:SCNI
Holding SCNI?
Track your performance easily
SCNI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.23 - $8.92
Previous CloseN/A
Volume8.73K
Average Volume (3M)8.78K
Market Cap
$2.99M
Enterprise Value$8.60M
Total Cash (Recent Filing)$17.72M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)11.5
Beta1.24
Next Earnings
May 29, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.30
Shares Outstanding852,996
10 Day Avg. Volume6,787
30 Day Avg. Volume8,778
Standard Deviation0.28
R-Squared0.19
Alpha-0.06
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap2.88
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.63
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Scinai Immunotherapeutics News
PremiumCompany Announcements
Scinai Immunotherapeutics Reports Financial Turnaround and Growth
PremiumCompany Announcements
Scinai Immunotherapeutics Gains Shareholder Confidence
PremiumCompany Announcements
Scinai Immunotherapeutics to Hold Annual Shareholder Meeting
PremiumCompany Announcements
Scinai Immunotherapeutics Licenses Global RightsPremiumCompany Announcements
Scinai Immunotherapeutics Restructures Debt, Eyes Growth
PremiumCompany Announcements
Scinai Immunotherapeutics Back on Track with Nasdaq
PremiumCompany Announcements
Scinai Immunotherapeutics Restructures Debt, Boosts EquityOwnership Overview
7.40%
Insiders
0.02% Mutual Funds
<0.01% Other Institutional Investors
92.58% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SCNI FAQ
What was Scinai Immunotherapeutics’s price range in the past 12 months?
Scinai Immunotherapeutics lowest stock price was $2.23 and its highest was $8.92 in the past 12 months.
What is Scinai Immunotherapeutics’s market cap?
Scinai Immunotherapeutics’s market cap is $2.99M.
When is Scinai Immunotherapeutics’s upcoming earnings report date?
Scinai Immunotherapeutics’s upcoming earnings report date is May 29, 2025 which is in 118 days.
How were Scinai Immunotherapeutics’s earnings last quarter?
Scinai Immunotherapeutics released its earnings results on Nov 22, 2024. The company reported $0.002 earnings per share for the quarter, beating the consensus estimate of N/A by $0.002.
Is Scinai Immunotherapeutics overvalued?
According to Wall Street analysts Scinai Immunotherapeutics’s price is currently Overvalued.
Does Scinai Immunotherapeutics pay dividends?
Scinai Immunotherapeutics does not currently pay dividends.
What is Scinai Immunotherapeutics’s EPS estimate?
Scinai Immunotherapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scinai Immunotherapeutics have?
Scinai Immunotherapeutics has 852,996 shares outstanding.
What happened to Scinai Immunotherapeutics’s price movement after its last earnings report?
Scinai Immunotherapeutics reported an EPS of $0.002 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 17.219%.
Which hedge fund is a major shareholder of Scinai Immunotherapeutics?
Currently, no hedge funds are holding shares in SCNI
---
Company Description
Scinai Immunotherapeutics
BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases. It works on M-001, a synthetic peptide-based protein targeting both seasonal and pandemic strains of the influenza virus. The company was founded by Ron Babecoff and Rami Epstein on July 22, 2003 and is headquartered in Jerusalem, Israel.
---
Technical Analysis
MacroGenics
―
Fate Therapeutics
―
Karyopharm Therapeutics
―
Adaptimmune Therapeutics
―
Immatics
―
---